EP3946380A4 - Compositions and methods for cancer immunotherapy - Google Patents

Compositions and methods for cancer immunotherapy Download PDF

Info

Publication number
EP3946380A4
EP3946380A4 EP20783457.3A EP20783457A EP3946380A4 EP 3946380 A4 EP3946380 A4 EP 3946380A4 EP 20783457 A EP20783457 A EP 20783457A EP 3946380 A4 EP3946380 A4 EP 3946380A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
cancer immunotherapy
immunotherapy
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20783457.3A
Other languages
German (de)
French (fr)
Other versions
EP3946380A1 (en
Inventor
Houn Simon Hsia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP3946380A1 publication Critical patent/EP3946380A1/en
Publication of EP3946380A4 publication Critical patent/EP3946380A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
EP20783457.3A 2019-04-01 2020-03-31 Compositions and methods for cancer immunotherapy Pending EP3946380A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962827429P 2019-04-01 2019-04-01
US201962895421P 2019-09-03 2019-09-03
PCT/US2020/026000 WO2020205885A1 (en) 2019-04-01 2020-03-31 Compositions and methods for cancer immunotherapy

Publications (2)

Publication Number Publication Date
EP3946380A1 EP3946380A1 (en) 2022-02-09
EP3946380A4 true EP3946380A4 (en) 2022-12-21

Family

ID=72666556

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20783457.3A Pending EP3946380A4 (en) 2019-04-01 2020-03-31 Compositions and methods for cancer immunotherapy

Country Status (9)

Country Link
US (1) US20220175850A1 (en)
EP (1) EP3946380A4 (en)
JP (2) JP2022519946A (en)
KR (1) KR20220003528A (en)
CN (1) CN114072155A (en)
CA (1) CA3135381A1 (en)
IL (1) IL286792A (en)
TW (1) TW202102236A (en)
WO (1) WO2020205885A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114720688B (en) * 2022-06-08 2022-09-06 中国医学科学院肿瘤医院 EVs membrane protein marker for predicting drug effect of lung cancer immune-chemotherapy combination

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160317593A1 (en) * 2013-03-28 2016-11-03 Houn Simon Hsia Nutritional composition
WO2018231937A2 (en) * 2017-06-13 2018-12-20 Houn Simon Hsia Compositions and methods for enhancing cancer radiotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008513521A (en) * 2004-09-21 2008-05-01 ベラコル セラピューティクス プロプライエタリー リミテッド Inorganic selenium for treating cancer
HU227588B1 (en) * 2004-12-03 2011-09-28 Sinnex Mueszaki Fejlesztoe Es Tanacsado Kft Antiviral and immunostimulant pharmaceutical composition containing polyunsaturated fatty acid esters
WO2010138902A1 (en) * 2009-05-29 2010-12-02 New Chapter Inc. Compositions and methods for modulating lipid composition
CN101843605A (en) * 2010-05-25 2010-09-29 福建医科大学附属协和医院 Emodin as inhibitor of activated molecules p-Akt and p-mTOR of PI3K/Akt/mTOR signal transduction pathway and application thereof
CN104146248B (en) * 2014-07-30 2016-06-01 广州施健生物科技有限公司 A kind of immunity nourishment composition and application thereof
TWI794171B (en) * 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-l1 inhibitors
IT201600111877A1 (en) * 2016-11-07 2018-05-07 Biouniversa Srl Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use
JP2020523370A (en) * 2017-06-13 2020-08-06 シャー, ホウン・サイモンHsia, Houn Simon Compositions and methods for enhancing cancer chemotherapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160317593A1 (en) * 2013-03-28 2016-11-03 Houn Simon Hsia Nutritional composition
WO2018231937A2 (en) * 2017-06-13 2018-12-20 Houn Simon Hsia Compositions and methods for enhancing cancer radiotherapy

Also Published As

Publication number Publication date
JP2023155416A (en) 2023-10-20
IL286792A (en) 2021-10-31
KR20220003528A (en) 2022-01-10
TW202102236A (en) 2021-01-16
JP2022519946A (en) 2022-03-25
WO2020205885A1 (en) 2020-10-08
CN114072155A (en) 2022-02-18
US20220175850A1 (en) 2022-06-09
EP3946380A1 (en) 2022-02-09
CA3135381A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
IL288754A (en) Compositions and methods for cancer immunotherapy
EP3765608A4 (en) Gene-regulating compositions and methods for improved immunotherapy
EP3765094A4 (en) Gene-regulating compositions and methods for improved immunotherapy
EP3589373A4 (en) Compositions and methods for immunotherapy
EP3765092A4 (en) Gene-regulating compositions and methods for improved immunotherapy
EP3983445A4 (en) Compositions and methods for treating cancer
AU2019343184A1 (en) Compositions and methods for treating cancer with anti-CD123 immunotherapy
EP3938354A4 (en) Compositions and methods for treating cancer
EP3703711A4 (en) Compositions and methods for treating cancer with anti-ror1 immunotherapy
EP3500262A4 (en) Compositions and methods for cancer immunotherapy
EP3917546A4 (en) Gene-regulating compositions and methods for improved immunotherapy
EP3891272A4 (en) Compositions and methods for immunotherapy
EP3968785A4 (en) Compositions and methods for treating cancer
EP4058062A4 (en) Compositions and methods for immunotherapy
EP3946456A4 (en) Targeted synergistic cancer immunotherapy
EP3965896A4 (en) Compositions and methods for treating cancer
IL283076A (en) Methods and compositions for cancer immunotherapy
EP3908601A4 (en) Methods and compositions for treating cancer
EP4045054A4 (en) Nano-enabled immunotherapy in cancer
EP4003351A4 (en) Methods and compositions for treating cancer
IL292872A (en) Compositions and methods for immunotherapy
EP3752194A4 (en) Compositions and methods for tumor immunotherapy
EP3773585A4 (en) Compositions and methods for treating cancer
EP4025204A4 (en) Cancer immunotherapy
EP3986443A4 (en) Combination cancer immunotherapy

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211008

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20221121

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20221115BHEP

Ipc: A61K 31/202 20060101ALI20221115BHEP

Ipc: A61K 35/60 20060101ALI20221115BHEP

Ipc: A61K 33/04 20060101AFI20221115BHEP